{"id":"W2971577153","doi":"10.1016/s1474-4422(19)30239-x","title":"Safety and efficacy of ozanimod versus interferon beta-1a in relapsing multiple sclerosis (SUNBEAM): a multicentre, randomised, minimum 12-month, phase 3 trial","year":2019,"lang":"en","type":"article","venue":"The Lancet Neurology","topic":"Multiple Sclerosis Research Studies","field":"Medicine","cited_by":286,"is_retracted":false,"has_abstract":false,"ca_institutions":"St. Michael's Hospital; McGill University; University of Toronto; NeuroRx Research (Canada)","funders":"Schweizerische Multiple Sklerose Gesellschaft; Bayer Schering; Javna Agencija za Raziskovalno Dejavnost RS; Ministerstvo Školství, Mládeže a Tělovýchovy; Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung; Sanofi; European Commission; Bayer; Celgene; Biogen; AbbVie; MedImmune; Merck; Teva Pharmaceutical Industries; Novartis; Roche","keywords":"Medicine; Internal medicine; Population; Clinical endpoint; Placebo; Clinical trial; Physical therapy; Pathology; Alternative medicine","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002802466,0.001669569,0.00397879,0.0003879459,0.0006345303,0.001350585,0.0009312915,0.002333637,0.006880342],"category_scores_gemma":[0.002345096,0.0007716225,0.00300216,0.0004282352,0.001445953,0.001489856,0.0006888434,0.003561522,0.001138967],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0008908054,"about_ca_system_score_gemma":0.001157589,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001060498,"about_ca_topic_score_gemma":0.00210344,"domain_scores_codex":[0.9988311,0.0006988826,0.00006878226,0.000163916,0.00007448976,0.0001627987],"domain_scores_gemma":[0.9984372,0.0005510219,0.0003843289,0.0001400813,0.000079274,0.0004081258],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9902651,0.001124625,0.0003869051,0.0003231982,0.0005727433,0.0000159323,0.00003949643,0.0001524514,0.0008660046,0.00004046724,0.0003364771,0.005876601],"study_design_scores_gemma":[0.9698008,0.02750585,0.001724142,0.00003247982,0.0003044133,0.00002183155,0.00002034564,0.0001391555,0.0001319258,0.0001010391,0.0002066973,0.00001141659],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9906529,0.004735714,0.0003896659,0.0006460428,0.0003596824,0.001145437,0.0008453416,0.00008378881,0.001141343],"genre_scores_gemma":[0.9903721,0.002054269,0.001202275,0.001059636,0.0003080926,0.002000123,0.000932848,0.00003223427,0.002038351],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.006880342,"threshold_uncertainty_score":0.02301705,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.0951953261825901,"score_gpt":0.3336784796590158,"score_spread":0.2384831534764257,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}